How do you judge the real value of a new Alzheimer’s drug?
Canada’s Drug Expert Committee reversed its earlier stance and now recommends conditional public funding for lecanemab, a drug that modestly slows early Alzheimer’s symptoms. The drug costs about $30,000 per patient annually, with projected provincial expenditures of $66 million in the first year and $485 million by the third year. Implementation challenges include strict eligibility criteria, biweekly infusions, and required MRI monitoring, raising questions about the optimal use of public healthcare funds.
- ▪The Canadian Drug Expert Committee changed its recommendation from not reimbursing lecanemab to supporting conditional reimbursement.
- ▪Clinical trials showed lecanemab can delay cognitive decline by five to seven months over an 18‑month period.
- ▪The drug costs roughly $30,000 per year per patient, leading to projected costs of $66 million in year one and $485 million by year three for provincial plans.
- ▪Eligibility requires a diagnosis of mild cognitive impairment or mild dementia, APOE4 genetic testing, biweekly infusions, and regular MRI scans.
- ▪The article highlights concerns about whether the public health system can effectively deliver the treatment and whether the funds might be better allocated to other dementia care services.
The Globe and Mail publishes from Canada and files mainly under world. We currently carry 1,935 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Globe and Mail |
| Canonical URL | https://www.theglobeandmail.com/opinion/article-new-alzheimers-drug-lecanemab-canada/ |
| Publication time | Fri, 24 Jul 2026 10:00:00 +0000 |
| Retrieval time | 2026-07-24T10:07:36.524Z |
| Last seen | 2026-07-24T10:07:36.524Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 4yo-j0WblGFb |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Open this photo in gallery:A woman receives Lecanemab, sold under the brand name Leqembi, at a hospital in Itabashi Ward, Tokyo. The Canadian Drug Expert Committee has shifted their stance, and is recommending that lecanemab should be publicly funded with conditions.Kota Kiriyama/ReutersShareSave for laterPlease log in to bookmark this story.Log InCreate Free AccountAn expert committee at Canada’s Drug Agency has changed its mind: In February, it said public drug plans should not fund lecanemab, a drug used to treat the early symptoms of Alzheimer’s. Now, in July, after a “reconsideration process,” it is recommending that lecanemab be funded publicly – sometimes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Globe and Mail.
Discussion
0 commentsMore from The Globe and Mail
